Patent ID: 8481279
Filing Date: 2013-07-09
Classification: A61K,C07K,C12N,C12Q,G01N,Y10T

Abstract:
1. A method for inhibiting the progression of a lung cancer that expresses a human Echinoderm Microtubule-Associated Protein-Like 4 (EML4)-Anaplastic Lymphoma Kinase (ALK) fusion polypeptide in a human patient wherein the EML4-ALK fusion polypeptide comprises an amino acid having at least 95% identity with an amino acid sequence comprising residues 1-222 of SEQ ID NO: 3 and residues 1116-1383 of SEQ ID NO: 5, the method comprising administering to the patient an effective amount of a small molecule compound that directly inhibits the kinase activity of ALK, wherein the patient has been identified as having a lung cancer expressing the EML4-ALK fusion polypeptide.